Clinical trials: Allergy and Immunology

Allergy and Immunology

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

• Terminated
• Age: 18 to 65 years
• Phase 1
• Injection or infusion

This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects.

Trial name

NCT02559258

Where

Australia

Volunteers

5 people, healthy volunteers welcome

Sponsor

Tunitas Therapeutics, Inc.